Pfizer has received EC approval to expand the Hympavzi indication to treat haemophilia A or B with inhibitors in patients aged 12 years and over.

Streeting’s resignation comes in the wake of the Labour party’s poor performance in the local elections, held on 7 May.

Four cancer drugs have got the FDA nod in May thus far, with approvals spanning haematological and solid tumour indications.

Coya Therapeutics has received fast track designation from the US FDA for COYA 302, an investigational biologic combination therapy to treat ALS.

Zydus Lifesciences is set to acquire all outstanding Assertio common shares in a $166.4m deal, via its subsidiary Zydus Worldwide DMCC.

AstraZeneca’s Imfinzi (durvalumab) will become the first immunotherapy available for UK National Health Service (NHS) patients with an aggressive form of stomach cancer, after a ...

At ECO 2026, researchers presented a study assessing fasting PYY, ghrelin and GIP levels in T1D patients, with or without obesity.

At ECO 2026, findings from the ATTAIN-MAINTAIN trial were presented, assessing (orforglipron) for maintaining body weight loss in obese or overweight adults.

Data from the REDEFINE-1 trial (NCT05567796) were recently presented in Türkiye, assessing Novo Nordisk's CagriSema in adults with obesity.

Agreement on the proposed Critical Medicines Act (CMA) represents an important step for boosting the EU pharma sector.

Isomorphic Labs has secured $2.1bn in funding to expedite its transition from developing AI models to deploying them on a larger scale.

This FDA framework comes as significant knowledge gaps remain around the efficacy and safety of drugs in pregnancy and lactation.